NASDAQ: GOSSGossamer Bio Inc Stock
$0.16+0.00 (+0%)
Updated Aug 21, 2026
Gossamer Bio shares are trading... find out Why GOSS Price Moved with a free WallStreetZen account
Why Price MovedGOSS Price
$0.16
Fair Value Price
$0.10
Market Cap
$75.77M
52 Week Low
$0.11
52 Week High
$3.87
P/E
-0.27x
P/B
-0.81x
P/S
0.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$53.29M
Earnings
-$125.22M
Gross Margin
100%
Operating Margin
-214.6%
Profit Margin
-235%
Debt to Equity
-1.82
Operating Cash Flow
-$163M
Beta
1.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GOSS Overview
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GOSS's potential to beat the market
- GOSS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GOSS
RankedUnranked of 470
RankedUnranked of 470
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $122.25 | A | |
| $7.20 | A |
Be the first to know about important GOSS news, forecast changes, insider trades & much more!
GOSS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GOSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GOSS ($0.16) is overvalued by 49.89% relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GOSS ($0.16) is not significantly undervalued (49.89%) relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOSS due diligence checks available for Premium users.
Valuation
GOSS fair value
Fair Value of GOSS stock based on Discounted Cash Flow (DCF)
Price
$0.16
Fair Value
$0.10
Overvalued by
54.72%
GOSS ($0.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOSS ($0.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GOSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
18.13x
Market
18.35x
GOSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.81x
Industry
5.61x
GOSS's financial health
Profit margin
Revenue
$9.2M
Net Income
$16.9M
Profit Margin
182.9%
GOSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GOSS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.9M
Liabilities
$170.9M
Debt to equity
-1.82
GOSS's short-term liabilities ($137.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOSS's short-term assets ($72.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOSS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GOSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.4M
Investing
$42.7M
Financing
-$3.1M
GOSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GOSS vs Biotech Stocks
Gossamer Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.